Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) is a clonal malignancy characterized by the expansion of small B lymphocytes and accumulation of CLL cells. This disease is the most common form of leukemia in the Western hemisphere and is currently not considered to be curable using currently available therapies. Published reports have suggested that purine analogues have activity in B-CLL and superior to alkylating agents. Even though responses have been observed with purine analogues that are used as single agents, these responses were not durable. The use of combination purine analogue therapy with alkylating agents and/or monoclonal antibodies was then explored in order to take advantage of synergistic actions of these agents to improve the quality of clinical responses. Both fludarabine and pentostatin have shown improved responses when combined with alkylating agents and even higher overall and complete responses (CRs) when combined with monoclonal antibodies.

Original languageEnglish (US)
JournalSeminars in Hematology
Volume43
Issue numberSUPPL. 2
DOIs
StatePublished - Apr 2006

Fingerprint

Alkylating Agents
B-Cell Chronic Lymphocytic Leukemia
Drug Therapy
Monoclonal Antibodies
Pentostatin
Leukemia
B-Lymphocytes
Therapeutics
purine
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

@article{d3bd3ef9ceb04264ae5fb9573084daff,
title = "Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia",
abstract = "B-cell chronic lymphocytic leukemia (B-CLL) is a clonal malignancy characterized by the expansion of small B lymphocytes and accumulation of CLL cells. This disease is the most common form of leukemia in the Western hemisphere and is currently not considered to be curable using currently available therapies. Published reports have suggested that purine analogues have activity in B-CLL and superior to alkylating agents. Even though responses have been observed with purine analogues that are used as single agents, these responses were not durable. The use of combination purine analogue therapy with alkylating agents and/or monoclonal antibodies was then explored in order to take advantage of synergistic actions of these agents to improve the quality of clinical responses. Both fludarabine and pentostatin have shown improved responses when combined with alkylating agents and even higher overall and complete responses (CRs) when combined with monoclonal antibodies.",
author = "Kay, {Neil Elliot}",
year = "2006",
month = "4",
doi = "10.1053/j.seminhematol.2005.12.011",
language = "English (US)",
volume = "43",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia

AU - Kay, Neil Elliot

PY - 2006/4

Y1 - 2006/4

N2 - B-cell chronic lymphocytic leukemia (B-CLL) is a clonal malignancy characterized by the expansion of small B lymphocytes and accumulation of CLL cells. This disease is the most common form of leukemia in the Western hemisphere and is currently not considered to be curable using currently available therapies. Published reports have suggested that purine analogues have activity in B-CLL and superior to alkylating agents. Even though responses have been observed with purine analogues that are used as single agents, these responses were not durable. The use of combination purine analogue therapy with alkylating agents and/or monoclonal antibodies was then explored in order to take advantage of synergistic actions of these agents to improve the quality of clinical responses. Both fludarabine and pentostatin have shown improved responses when combined with alkylating agents and even higher overall and complete responses (CRs) when combined with monoclonal antibodies.

AB - B-cell chronic lymphocytic leukemia (B-CLL) is a clonal malignancy characterized by the expansion of small B lymphocytes and accumulation of CLL cells. This disease is the most common form of leukemia in the Western hemisphere and is currently not considered to be curable using currently available therapies. Published reports have suggested that purine analogues have activity in B-CLL and superior to alkylating agents. Even though responses have been observed with purine analogues that are used as single agents, these responses were not durable. The use of combination purine analogue therapy with alkylating agents and/or monoclonal antibodies was then explored in order to take advantage of synergistic actions of these agents to improve the quality of clinical responses. Both fludarabine and pentostatin have shown improved responses when combined with alkylating agents and even higher overall and complete responses (CRs) when combined with monoclonal antibodies.

UR - http://www.scopus.com/inward/record.url?scp=33644994706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644994706&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2005.12.011

DO - 10.1053/j.seminhematol.2005.12.011

M3 - Article

C2 - 16549115

AN - SCOPUS:33644994706

VL - 43

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - SUPPL. 2

ER -